New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;FB;PMFG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
November 28, 2014
13:09 EDTFBOptions Update; November 28, 2014
Subscribe for More Information
09:40 EDTFBActive equity options trading
Subscribe for More Information
November 26, 2014
16:01 EDTFBOptions Update; November 26, 2014
Subscribe for More Information
13:25 EDTBMYAchillion to benefit from Bristol-Myers CRL, says FBR Capital
FBR Capital expects Achillion (ACHN) to benefit from the complete response letter that the FDA sent to Bristol-Myers (BMY) on its daclatasvir HCV drug. The firm thunks the letter increases the value of GT-3 HCV patients for Achillion. FBR says that GT-3 patients constitute 5% of HCV patients in the U.S. and significantly higher in Europe. It keeps an Outperform rating on Achillion.
11:38 EDTBMYBristol-Myers receives CRL from FDA for daclatasvir
Subscribe for More Information
11:36 EDTBMYBristol-Myers receives CRL from FDA for daclatasvir
Subscribe for More Information
09:35 EDTFBActive equity options trading
Active equity options trading according to Track Data: AAPL HPQ SDRL TASR FB TXN NFLX AMZN TWTR PBR
November 25, 2014
16:02 EDTFBApple Tesla Twitter Facebook Netflix
Subscribe for More Information
13:16 EDTFBAngie's List retreats after Amazon reportedly launches local services site
Shares of Angie's List (ANGI) are sinking after The Wall Street Journal reported this morning that Amazon.com (AMZN) had launched a website that will connect consumers to local service providers. Angie's List connects users to local contractors and publishes consumers' reviews of contractors. WHAT'S NEW: Amazon.com launched its website featuring information about local contractors in New York, Los Angeles, and Seattle, The Journal reported, citing an unnamed source who was briefed on the company's plan. Called Amazon Local Services, the website is part of the e-commerce giant's attempt to compete with traditional stores, The Journal said. WHAT'S NOTABLE: Reuters reported last June that Amazon planned to launch a local services website. Last month, research firm Wunderlich said that Angie's List could be a logical takeover target for Amazon or eBay (EBAY). Wunderlich issued its note after The Financial Times reported that Angie's List had hired bankers to help it explore strategic options, including a possible sale of the company. ANALYST REACTION: In a note to investors today, Robert W. Baird analyst Colin Sebastian wrote that Amazon's service should be appealing to users searching for local services or shopping for products that have to be serviced. Moreover, service providers should also find value in Amazon's website, Sebastian stated. Service providers will only have to pay Amazon a share of the revenue they receive from customers they obtain from the website, the analyst wrote. Also, Amazon's popularity will enable it to bring meaningful amounts of business to the service providers, Sebastian wrote. He kept a $340 price target and Outperform rating on Amazon shares. Sebastian also noted that the market is increasingly competitive, with Groupon (GRPN) and Yelp (YELP) among the other public companies in the space, and he said he expects Facebook (FB) and Google (GOOG) to build more local services over time. PRICE ACTION: In early afternoon trading, Angie's List fell 4% to $6 and Amazon slid 1% to $332.50.
November 24, 2014
16:00 EDTFBOptions Update; November 24, 2014
Subscribe for More Information
09:00 EDTBMYBristol-Myers, Five Prime announce clinical collaboration for Opdivo, FPA008
Subscribe for More Information
November 21, 2014
06:08 EDTFBFacebook working to expand drone team, Re/code reports
Subscribe for More Information
November 19, 2014
14:25 EDTFBOptions Update; November 14, 2014
Subscribe for More Information
09:39 EDTFBActive equity options trading on open
Subscribe for More Information
07:52 EDTBMYInforma Business Information to hold a conference
Subscribe for More Information
06:07 EDTBMYBristol-Myers' Opdivo for melanoma shows positive Phase 3 results
Subscribe for More Information
November 18, 2014
12:54 EDTFBFacebook introduces FB Techwire breaking tech news product
Facebook, in a post to its media blog, announced the launch of FB Techwire, a resource for journalists to discover original content including breaking news, first-person analysis, photos and videos posted to Facebook by technology influencers and organizations. Reference Link
11:07 EDTFBStocks with call strike movement; DAL FB
Subscribe for More Information
09:32 EDTFBActive equity options trading according to Track Data: AAPLTSLA TWTR FB
Subscribe for More Information
08:44 EDTFBFacebook initiated with a Long-Term Buy at Hilliard Lyons
Subscribe for More Information
07:57 EDTFBFacebook At Work unlikely to impact LinkedIn, says Wunderlich
Subscribe for More Information
06:08 EDTFBIntel's 'Mica' bracelet to feature Google alerts, AT&T data plan, Re/code says
Subscribe for More Information
November 17, 2014
16:00 EDTFBOptions Update; November 17, 2014
Subscribe for More Information
14:56 EDTFBFacebook reports solid October engagement data, says JPMorgan
12:42 EDTFBProfessional network operators slide following report on 'Facebook at Work'
Subscribe for More Information
11:06 EDTBMYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:36 EDTFBActive equity options trading
Active equity options trading according to Track Data: AAPL PBR BHI GILD MU HD AMZN TSLA YHOO FB TWTR
08:13 EDTBMYPortola, Bristol-Myers, Pfizer announce results from Phase 3 ANNEXA-A studies
Subscribe for More Information
08:10 EDTBMYBristol-Myers presents results from Phase IIIb AVERT trial at ACR
Bristol-Myers Squibb Company announced results of several new sub-analyses of the Phase IIIb AVERT trial that investigated the use of Orencia plus methotrexate in biologic and MTX-naïve citrullinated protein-positive early moderate to severe rheumatoid arthritis patients. These data were presented this week at the American College of Rheumatology 2014 annual meeting. Orencia is currently indicated in adults for moderate to severe RA. Orencia should not be administered with tumor necrosis factor antagonists and should not be used with other biologic RA drugs. One of the analyses looked at anti-CCP antibodies, which are a marker of RA and may contribute to disease progression. The analysis assessed the development of anti-CCP antibodies in patients with early rapidly progressing RA by measuring isotypes and the number of epitopes recognized after treatment with Orencia plus MTX, Orencia alone, or MTX alone. Results demonstrated Orencia plus MTX numerically reduced the concentrations of all CCP isotypes and the average number of epitopes recognized over one year of treatment more than Orencia alone or MTX alone. Over 12 months of treatment, 6.7 percent, 12.1 percent, and 7.8 percent of patients on Orencia plus MTX, Orencia alone, and MTX alone, respectively, experienced a serious adverse event and 1.7 percent, 4.3 percent and 2.6 percent led to discontinuation. Serious infections were observed in 0.8 percent of patients in the combination arm and 3.4 percent in the Orencia monotherapy arm. None of the patients in the MTX alone arm experienced a serious infection. Malignancies were reported in 0.8 percent, 1.7 percent, and 0 percent of patients in the Orencia + MTX, Orencia, and MTX arms, respectively. Additionally at ACR, investigators presented 12-month efficacy data from AVERT, including new results assessing the effect of Orencia on more clinically stringent remission criteria than DAS-defined remission, as well as new MRI data. Significantly more patients on Orencia plus MTX achieved the stringent clinical endpoint of Boolean-defined remission at 12 months.
06:30 EDTFBFacebook says reducing 'overly promotional' page posts in news feed
Facebook said on Friday that "Our goal with News Feed has always been to show people the things they want to see. That’s why we often look to people on Facebook to tell us how we can improve. As part of an ongoing survey we asked hundreds of thousands of people how they feel about the content in their News Feeds. People told us they wanted to see more stories from friends and Pages they care about, and less promotional content. What we discovered is that a lot of the content people see as too promotional is posts from Pages they like, rather than ads. This may seem counterintuitive but it actually makes sense: News Feed has controls for the number of ads a person sees and for the quality of those ads, but those same controls haven’t been as closely monitored for promotional Page posts. Now we’re bringing new volume and content controls for promotional posts, so people see more of what they want from Pages.... Beginning in January 2015, people will see less of this type of content in their News Feeds. This change will not increase the number of ads people see in their News Feeds. The idea is to increase the relevance and quality of the overall stories – including Page posts – people see in their News Feeds. This change is about giving people the best Facebook experience possible and being responsive to what they have told us. While Pages that post a lot of the content we mention above will see a significant decrease in distribution, the majority of Pages will not be impacted by this change." Reference Link
06:23 EDTFBFacebook working on 'Facebook at Work' website, FT reports
Subscribe for More Information
November 16, 2014
13:07 EDTBMYBristol-Myers announces results from CheckMate -066 study
Subscribe for More Information
November 14, 2014
17:07 EDTFBSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
16:01 EDTFBOptions Update; November 14, 2014
Subscribe for More Information
14:53 EDTBMYCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
07:32 EDTFBHayman Capital gives quarterly update on stakes
Subscribe for More Information
07:14 EDTBMYAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
06:24 EDTFBFacebook implied volatility of 27 at lower end of index mean range
06:05 EDTBMYBristol-Myers to construct biologics manufacturing facility in Ireland
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use